Prof. dr. Nancy Bocken appointed as Professor Sustainable Business
Prof. dr. Nancy Bocken is appointed as fulltime Professor Sustainable Business at the Maastricht Sustainability Institute – School of Business and Economics, Maastricht University as from 1 March 2020.
Nancy studied at Maastricht University (SBE) and holds a PhD from the University of Cambridge. She worked at the universities of Cambridge, Delft and Lund, and now she returns to Maastricht. The professorship in Sustainable Business will contribute significantly to research and education of the Maastricht Sustainability Institute and the new SBE 2025 Vision.
Nancy received recently the prestigious ERC starting grant for her new project CIRCULAR X. The project will develop a new field of research on experimentation with circular service business models (CSBMs) in the transition to a circular economy. In the upcoming year, Nancy will lead and work on this ambitious project for which new staff will be appointed.
Nancy’s main areas of interest are sustainable business models, business experiments for sustainability, sustainable innovation, scaling up sustainable business, closing the 'idea-action' gap in sustainability, and sufficiency oriented business approaches to slow consumption and resource usage.
Nancy will also be active in teaching and education. Currently, we are exploring the development of a (joint) Master programme Sustainable Business (working title) in the context of the York-Maastricht Partnership.
Also read
-
It probably hasn't escaped your attention that we are dealing with a disruption in our network. At the moment, the network varies from working just fine to being really slow or going down completely. The disruption has an external cause and is targeting the shared SURF servers of educational institutions. UM is therefore not the only institution experiencing problems.
-
Maastricht University (UM) will support the Université de Burundi with the development of educational programs in IT.
-
Obesity is one of the great public health problems we face. New drugs such as Ozempic offer possibilities but also raise moral, economic and health questions. Why is ‘just lose some weight’ naïve and unempirical? Why might covering Ozempic be cheaper for health insurers? We brought together experts Anne Roefs, Gijs Goossens and Mickaël Hiligsmann to talk about obesity and its new miracle cure.
